USPTO serial 85096180
NEUROFENCINE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- BROWN, BARBARA TROFFKIN
- Law office
- TMO LAW OFFICE 116 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with NEUROFENCINE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Animal feed additive for use as a nutritional supplement for medical purposes; Animal feed supplements; Anti-diabetic pharmaceuticals; Cardiovascular pharmaceuticals; Dietary and nutritional supplements; Dietary and nutritional supplements containing agmatine, G-agmatine; Dietary and nutritionally fortified food products adapted for medical use; Dietary beverage supplements for human consumption in liquid and dry mix form for therapeutic purposes; Dietary drink mix for use as a meal replacement; Dietary food supplements; Dietary pet supplements in the form of pet treats; Dietary supplement beverage for healthy nervous system; Dietary supplemental drinks; Dietary supplemental drinks in the nature of vitamin and mineral beverages; Dietary supplements; Dietary supplements also containing agmatine, G-agmatine; Dietary supplements for animals; Dietary supplements for human consumption; Dietary supplements for pets; Dietary supplements for pets in the nature of a powdered drink mix; Feed supplements for healthy nervous system; Food supplements; Foods for individuals with special dietary requirements necessitated by medical treatments; Health food supplements; Homeopathic pharmaceuticals for use in the treatment of nervous system damage; Homeopathic supplements; Liquid nutritional supplement; Meal replacement and dietary supplement drink mixes; Medicated supplements for foodstuffs for animals; Medicated supplements for foodstuffs for babies; Natural supplements for treating depression and anxiety; Non-medicated additives for animal feed for use as nutritional supplements; Nutraceuticals for use as a dietary supplement; Nutritional additives for medical purposes for use in foods and dietary supplements for human consumption; Nutritional additives for medical purposes used in foods and dietary supplements for human consumption; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplements; Nutritional supplements in capsule form for dogs; Nutritional supplements in lotion form sold as a component of nutritional skin care products; Ocular pharmaceuticals; Pharmaceutical preparations acting on the central nervous system; Pharmaceutical preparations and substances for the treatment of damaged skin and tissue; Pharmaceutical preparations and substances for the treatment of infectious diseases, blood disorders, pain, inflammation, sepsis, alopecia, obesity and cognitive disorders; Pharmaceutical preparations and substances for the treatment of psychiatric diseases and disorders; Pharmaceutical preparations and substances for the treatment of viral, metabolic, endocrine, musculoskeletal, cardiovascular, cardiopulmonary, genitourinary, sexual dysfunction, oncological, hepatological, ophthalmic, respiratory, neurological,gastrointestinal, hormonal, dermatological, psychiatric and immune system related diseases and disorders; Pharmaceutical preparations for skin care; Pharmaceutical preparations for the prevention and treatment of disorders of the nervous system, the immune system, the cardio-vascular system, the metabolic system, the respiratory system, the musculo-skeletal system, the genitourinary system; for thetreatment of inflammatory disorders; for use in dermatology, oncology, hematology and in tissue and organ transplantation, in ophthalmology and for gastroenterological disorders; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, bacteria-based diseases or disorders, autoimmune diseases or disorders, kidney diseases or disorders, and diabetes; Pharmaceutical preparations for the prevention and treatment of ocular disorders or diseases, for the treatment of bacteria-based diseases, and for the treatment of diabetes, and anti-infective preparations, antiviral preparations, antibiotics,antifungal preparations and vaccines; Pharmaceutical preparations for the prevention of nervous system damage; Pharmaceutical preparations for the treatment and prevention of nervous system damage; Pharmaceutical preparations for the treatment of eye diseases and conditions; Pharmaceutical preparations for the treatment of nervous system damage; Pharmaceutical preparations for treating diabetes; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for wounds; Pharmaceutical preparations for treatment and prevention of nervous system; Pharmaceutical preparations, namely, a topical preparation for the treatment of ocular disorders prescribed by ophthalmologists, eye surgeons, and optometrists; Pharmaceutical preparations, namely, an analgesic for human consumption taken orally; Pharmaceutical preparations, namely, antidepressants; Pharmaceutical products for ophthalmological use; Pharmaceutical skin lotions; Pharmaceutical solutions used in dialysis; Powdered nutritional supplement drink mix; Therapeutic pharmaceutical for the treatment of treatment and prevention of nervous system; Vitamins and dietary food supplements for animals | ACTIVE | Jan 27, 2010 |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Jun 20, 2011 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Jun 18, 2011 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 20, 2010 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 20, 2010 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 20, 2010 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Nov 12, 2010 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 3, 2010 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Aug 2, 2010 | NWAP | NEW APPLICATION ENTERED | — |